Izotropic is the only publicly traded company commercializing a dedicated Breast CT imaging platform, known as IzoView, which directly targets a major unmet need in breast cancer care. Unlike traditional mammography, which compresses breast tissue and can miss cancers in women with dense breasts, IzoView produces true 3D volumetric images in about 40 seconds — without compression, pain, or handlingThe company is entering final regulatory and pivotal clinical stages, with an FDA-aligned study in preparation and ongoing site partnerships for clinical deployment.early and accurate detection of breast cancer. As global incidence continues to climb, with millions of new cases each year, traditional imaging technologies often fail to identify tumors—particularly in women with dense breast tissue. Izotropic is pioneering a breakthrough approach through its proprietary 3D breast imaging technology, designed to deliver unparalleled precision, clarity, and diagnostic confidence. By enabling physicians to see cancers earlier and more accurately than ever before, Izotropic has the potential to save countless lives, reduce unnecessary biopsies, and transform patient care. Beyond individual outcomes, its innovation represents a major leap forward in healthcare equity, ensuring that all women—regardless of breast density—can access the most effective diagnostic tools available. In doing so, Izotropic is setting a new global standard for breast imaging and reshaping the future of cancer detection.
Breast cancer incidence continues to rise, with more than 2.3 million new cases diagnosed globally each year and approximately 315,000 expected in the United States in 2025. Nearly half of all women have dense breast tissue, a condition that significantly reduces the effectiveness of traditional mammography in detecting tumors. In response, new U.S. federal regulations now require that breast density information be disclosed in mammography reports, ensuring that patients are informed about their screening limitations. Furthermore, 38 U.S. states have implemented mandates requiring insurance coverage for supplemental screening methods, reinforcing a nationwide shift toward more accurate and personalized breast cancer detection.
Why Izotropic's tech is so revolutionary.40 seconds.Fully self-shielded radiation system that fits standard exam rooms.Spatial resolution 100× greater than MRI, offering sub-millimeter clarity.routinely detecting tumors as small as 2 millimeters, compared to the 11-millimeter average of mammography.This level of precision translates into an estimated 1.1 to 1.25 years of earlier detection, potentially offering a critical diagnostic advantage over standard imaging methods. Early detection is vital, as even a 10% delay in identifying cancer can reduce survival rates by more than 10% per month. In terms of performance, breast CT technology in academic research trials has been shown to deliver superior visualization of both malignant and benign lesions when compared to mammography and digital breast tomosynthesis (DBT), representing a significant leap forward in diagnostic accuracy and patient outcomes.
IzoView is also targeted to be more cost-effective and accessible than MRI, offering a faster and more streamlined workflow without the booking competition from other specialties. This simplicity not only reduces infrastructure and operational costs but also makes the system easier to implement across a wide range of healthcare settings. Its design is well-suited for broad adoption in clinics and imaging centers seeking to improve workflow efficiency while integrating AI-driven diagnostic tools, making it an ideal solution for institutions aiming to enhance precision imaging without increasing complexity or cost.
first-mover advantage in the dedicated Breast CT category.Proprietary imaging technology licensed from the University of California, Davis.intellectual property position.underserved market driven by regulatory change, patient demand, and AI-integration trends.Read more below.Izotropic is the only publicly traded company commercializing a dedicated Breast CT imaging platform, known as IzoView, which directly targets a major unmet need in breast cancer care. Unlike traditional mammography, which compresses breast tissue and can miss cancers in women with dense breasts, IzoView produces true 3D volumetric images in about 40 seconds — without compression, pain, or handlingThe company is entering final regulatory and pivotal clinical stages, with an FDA-aligned study in preparation and ongoing site partnerships for clinical deployment.early and accurate detection of breast cancer. As global incidence continues to climb, with millions of new cases each year, traditional imaging technologies often fail to identify tumors—particularly in women with dense breast tissue. Izotropic is pioneering a breakthrough approach through its proprietary 3D breast imaging technology, designed to deliver unparalleled precision, clarity, and diagnostic confidence. By enabling physicians to see cancers earlier and more accurately than ever before, Izotropic has the potential to save countless lives, reduce unnecessary biopsies, and transform patient care. Beyond individual outcomes, its innovation represents a major leap forward in healthcare equity, ensuring that all women—regardless of breast density—can access the most effective diagnostic tools available. In doing so, Izotropic is setting a new global standard for breast imaging and reshaping the future of cancer detection.
Breast cancer incidence continues to rise, with more than 2.3 million new cases diagnosed globally each year and approximately 315,000 expected in the United States in 2025. Nearly half of all women have dense breast tissue, a condition that significantly reduces the effectiveness of traditional mammography in detecting tumors. In response, new U.S. federal regulations now require that breast density information be disclosed in mammography reports, ensuring that patients are informed about their screening limitations. Furthermore, 38 U.S. states have implemented mandates requiring insurance coverage for supplemental screening methods, reinforcing a nationwide shift toward more accurate and personalized breast cancer detection.
Why Izotropic's tech is so revolutionary.40 seconds.Fully self-shielded radiation system that fits standard exam rooms.Spatial resolution 100× greater than MRI, offering sub-millimeter clarity.routinely detecting tumors as small as 2 millimeters, compared to the 11-millimeter average of mammography.This level of precision translates into an estimated 1.1 to 1.25 years of earlier detection, potentially offering a critical diagnostic advantage over standard imaging methods. Early detection is vital, as even a 10% delay in identifying cancer can reduce survival rates by more than 10% per month. In terms of performance, breast CT technology in academic research trials has been shown to deliver superior visualization of both malignant and benign lesions when compared to mammography and digital breast tomosynthesis (DBT), representing a significant leap forward in diagnostic accuracy and patient outcomes.
IzoView is also targeted to be more cost-effective and accessible than MRI, offering a faster and more streamlined workflow without the booking competition from other specialties. This simplicity not only reduces infrastructure and operational costs but also makes the system easier to implement across a wide range of healthcare settings. Its design is well-suited for broad adoption in clinics and imaging centers seeking to improve workflow efficiency while integrating AI-driven diagnostic tools, making it an ideal solution for institutions aiming to enhance precision imaging without increasing complexity or cost.
first-mover advantage in the dedicated Breast CT category.Proprietary imaging technology licensed from the University of California, Davis.intellectual property position.underserved market driven by regulatory change, patient demand, and AI-integration trends.Read more below.https://izocorp.com/
https://izocorp.com/investors/presentation/
https://izocorp.com/site/assets/files/6166/izotropic_investor_presentation_breast_ct.pdf
IzoView & Breast CT Technology
Izotropic Corporation holds the exclusive global licensing rights to breast CT technology from the Regents of the University of California. This technology was originally developed at the University of California, Davis, under the Breast Tomography Project led by Company Director Dr. John Boone and his clinical collaborators. Four successive breast CT research devices were developed and evaluated at UC Davis. The clinical data and images referenced by Izotropic Corporation were generated using these research prototypes. IzoView, the commercial breast CT system developed by Izotropic Corporation, is a distinct and separate device designed for commercial use.
Accordingly, any clinical performance data or images referenced by the company should not be interpreted as evidence of IzoView’s abilities, safety or effectiveness. IzoView remains an investigational device and has not been evaluated in clinical trials or studies to support claims of diagnostic performance. No assurances are made that results achieved with earlier breast CT systems will be replicated with IzoView. The Company makes no claims or guarantees regarding the diagnostic capabilities, clinical benefits, or regulatory approval of IzoView at this time.
IzoView has not been approved or cleared by any regulatory authority and is not yet available for commercial sale. Any statements regarding potential clinical utility are for informational purposes only.
Izotropic is at a pivotal inflection point as it advances its proprietary IzoView Breast CT system into regulatory stages and commercial deployment.Unlike many early-stage medtech ventures, Izotropic’s platform isn’t conceptual — it’s fully engineered, tested, and validated through years of university-led research at UC Davis, supported by NIH funding and more than 50 peer-reviewed publications. Breast CT technology has shown superior detection accuracy, routinely identifying tumors as small as 2mm.This translates into potential earlier detection by more than a year, which could improve survival rates and lowering treatment costs. Technology studies have looked at malignant, benign, and microcalcified lesions, and support its broad application across screening and diagnostic workflows.
From a market perspective, Izotropic operates within a rapidly expanding imaging industry, projected to exceed $8.7 billion globally by 2030, with the U.S. segment alone reaching $1.55 billion. Regulatory tailwinds are also accelerating adoption: over 38 U.S. states now mandate supplemental screening coverage for women with dense breasts, and the FDA’s new breast density disclosure rule compels radiologists to inform patients when standard imaging may be insufficient. This creates a perfect convergence of policy, technology, and clinical need — a setting in which IzoView could become a new standard of care.
In comparison to market peers such as Hologic, Nanox, iCAD, Butterfly Network, and Lantheus, Izotropic stands out as a pure-play innovator in dedicated breast CT imaging — a niche yet high-growth category poised for disruption. While these peers have achieved valuations in the hundreds of millions to billions on similar technological advances, Izotropic remains relatively undervalued, offering significant asymmetric upside as it progresses toward FDA clearance and commercialization.
proven science, compelling economics, and clear market timing, aligning itself with the global movement toward earlier cancer detection and personalized imaging. For investors, the company represents a rare opportunity to participate in the redefinition of breast imaging — one that merges patient comfort, clinical precision, and commercial scalability in a single transformative platform.Izotropic is at a pivotal inflection point as it advances its proprietary IzoView Breast CT system into regulatory stages and commercial deployment.Unlike many early-stage medtech ventures, Izotropic’s platform isn’t conceptual — it’s fully engineered, tested, and validated through years of university-led research at UC Davis, supported by NIH funding and more than 50 peer-reviewed publications. Breast CT technology has shown superior detection accuracy, routinely identifying tumors as small as 2mm.This translates into potential earlier detection by more than a year, which could improve survival rates and lowering treatment costs. Technology studies have looked at malignant, benign, and microcalcified lesions, and support its broad application across screening and diagnostic workflows.
From a market perspective, Izotropic operates within a rapidly expanding imaging industry, projected to exceed $8.7 billion globally by 2030, with the U.S. segment alone reaching $1.55 billion. Regulatory tailwinds are also accelerating adoption: over 38 U.S. states now mandate supplemental screening coverage for women with dense breasts, and the FDA’s new breast density disclosure rule compels radiologists to inform patients when standard imaging may be insufficient. This creates a perfect convergence of policy, technology, and clinical need — a setting in which IzoView could become a new standard of care.
In comparison to market peers such as Hologic, Nanox, iCAD, Butterfly Network, and Lantheus, Izotropic stands out as a pure-play innovator in dedicated breast CT imaging — a niche yet high-growth category poised for disruption. While these peers have achieved valuations in the hundreds of millions to billions on similar technological advances, Izotropic remains relatively undervalued, offering significant asymmetric upside as it progresses toward FDA clearance and commercialization.
proven science, compelling economics, and clear market timing, aligning itself with the global movement toward earlier cancer detection and personalized imaging. For investors, the company represents a rare opportunity to participate in the redefinition of breast imaging — one that merges patient comfort, clinical precision, and commercial scalability in a single transformative platform.https://izocorp.com/
https://izocorp.com/investors/presentation/
https://izocorp.com/site/assets/files/6166/izotropic_investor_presentation_breast_ct.pdf
IzoView & Breast CT Technology
Izotropic Corporation holds the exclusive global licensing rights to breast CT technology from the Regents of the University of California. This technology was originally developed at the University of California, Davis, under the Breast Tomography Project led by Company Director Dr. John Boone and his clinical collaborators. Four successive breast CT research devices were developed and evaluated at UC Davis. The clinical data and images referenced by Izotropic Corporation were generated using these research prototypes. IzoView, the commercial breast CT system developed by Izotropic Corporation, is a distinct and separate device designed for commercial use.
Accordingly, any clinical performance data or images referenced by the company should not be interpreted as evidence of IzoView’s abilities, safety or effectiveness. IzoView remains an investigational device and has not been evaluated in clinical trials or studies to support claims of diagnostic performance. No assurances are made that results achieved with earlier breast CT systems will be replicated with IzoView. The Company makes no claims or guarantees regarding the diagnostic capabilities, clinical benefits, or regulatory approval of IzoView at this time.
IzoView has not been approved or cleared by any regulatory authority and is not yet available for commercial sale. Any statements regarding potential clinical utility are for informational purposes only.
